Hydrogel prodrug for treatment

Inventors

Fisher, Paul • Davis, Paulina

Assignees

Viking Scientific Inc

Abstract

Aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder. Without being limiting, the methods for treatment can be directed to a cancer, HIV, a virus, pain, a bacterial infection, a neurological disorder, hemorrhaging, multiple sclerosis, diabetes, high blood pressure, Alzheimer's, or inhibiting a fungal growth in a subject in need.

Core Innovation

The disclosure provides hydrogel prodrug delivery systems in which a drug that comprises at least one amine group is reacted with at least one acrylate in a polymerization reaction to produce at least one polymer prodrug, and polymerized polymer prodrug is incorporated into a hydrogel backbone. The hydrogel prodrug comprises a backbone structure in which the backbone comprises polymerized polymer prodrug, and the resulting hydrogel prodrug is provided in microparticle form.

The polymer prodrug is joined in a reaction mixture in the presence of a catalyst, thereby making the hydrogel prodrug. The disclosed systems further encompass tunable degradation and drug release behavior, including release behavior where drug release completion coincides with hydrogel degradation and controlled zero-order drug release kinetics.

The disclosure describes hydrogel prodrug microparticles that can be molded or cast into shapes including films, tablets, implants, scaffolds, microparticles, and pills, and further describes formulations that can include spacer chemistries, optional targeting moieties, and multi-drug compositions produced by blending multiple polymer prodrugs. Example drugs explicitly referenced include mesalamine, tranexamic acid, cisplatin, doxorubicin, and large biomolecules/antibodies.

Claims Coverage

Two independent claims are present, both directed to making a hydrogel prodrug in microparticle form. Across the independent claims, the core inventive features are reacting an amine-containing drug with an acrylate in a polymerization reaction to form a polymer prodrug, and joining the polymer prodrug into a backbone structure in the presence of a catalyst to create the hydrogel prodrug.

The independent claims cover methods that polymerize an acrylate with an amine-containing drug to create a polymer prodrug, join the polymer prodrug into a catalyst-formed backbone structure that includes polymerized polymer prodrug, and produce the hydrogel prodrug in microparticle form.

Stated Advantages

Documented Applications